{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:29:10Z","timestamp":1792632550559,"version":"4.5.0"},"reference-count":107,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2017,4,21]],"date-time":"2017-04-21T00:00:00Z","timestamp":1492732800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1007\/s40620-017-0404-z","type":"journal-article","created":{"date-parts":[[2017,4,21]],"date-time":"2017-04-21T11:08:55Z","timestamp":1492772935000},"page":"677-687","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":76,"title":["Osteoporosis, bone mineral density and CKD\u2013MBD: treatment considerations"],"prefix":"10.1093","volume":"30","author":[{"given":"Jordi","family":"Bover","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Bailone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00edctor","family":"L\u00f3pez-B\u00e1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Benito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Ciceri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Galassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Cozzolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,4,21]]},"reference":[{"issue":"2","key":"404_CR1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.bone.2005.11.024","volume":"38","author":"J-Y Reginster","year":"2006","unstructured":"Reginster J-Y, Burlet N (2006) Osteoporosis: a still increasing prevalence. Bone 38(2):4\u20139. doi: 10.1016\/j.bone.2005.11.024","journal-title":"Bone"},{"issue":"6","key":"404_CR2","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1001\/jama.285.6.785","volume":"285","author":"NIH Prevention","year":"2001","unstructured":"Prevention NIH (2001) Consensus development panel on osteoporosis prevention, diagnosis, and therapy. JAMA 285(6):785\u2013795. 10.1001\/jama.285.6.785","journal-title":"JAMA"},{"key":"404_CR3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1513724","author":"DM Black","year":"2016","unstructured":"Black DM, Rosen CJ (2016) Postmenopausal Osteoporosis. N Engl J Med (Table 1):595\u2013603. doi: 10.1056\/NEJMcp1513724","journal-title":"N Engl J Med"},{"issue":"3","key":"404_CR4","doi-asserted-by":"publisher","first-page":"743","DOI":"10.2106\/JBJS.I.00919","volume":"92","author":"A Unnanuntana","year":"2010","unstructured":"Unnanuntana A (2010) The assessment of fracture risk. J Bone Jt Surg 92(3):743. doi: 10.2106\/JBJS.I.00919","journal-title":"J Bone Jt Surg"},{"key":"404_CR5","volume-title":"The kidney","year":"2000","unstructured":"Llach F, Bover J, Brenner BM (eds) (2000) The kidney, 6th\u00a0edn. WB Sanders Company, ed., Philadelphia","edition":"6"},{"issue":"11","key":"404_CR6","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1038\/sj.ki.5000414","volume":"69","author":"S Moe","year":"2006","unstructured":"Moe S, Dr\u00fceke T, Cunningham J et al (2006) Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int 69(11):1945\u20131953. doi: 10.1038\/sj.ki.5000414","journal-title":"Kidney Int"},{"issue":"4","key":"404_CR7","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1097\/MNH.0000000000000131","volume":"24","author":"PT Goldenstein","year":"2015","unstructured":"Goldenstein PT, Jamal SA, Moyses RM (2015) Fractures in chronic kidney disease: pursuing the best screening and management. Curr Opin Nephrol Hypertens 24(4):317\u2013323. doi: 10.1097\/MNH.0000000000000131","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"1","key":"404_CR8","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s00198-013-2435-1","volume":"25","author":"M Maravic","year":"2014","unstructured":"Maravic M, Ostertag A, Torres PU, Cohen-Solal M (2014) Incidence and risk factors for hip fractures in dialysis patients. Osteoporos Int 25(1):159\u2013165. doi: 10.1007\/s00198-013-2435-1","journal-title":"Osteoporos Int"},{"issue":"7","key":"404_CR9","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1038\/sj.ki.5001754","volume":"70","author":"M Jadoul","year":"2006","unstructured":"Jadoul M, Albert JM, Akiba T et al (2006) Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the dialysis outcomes and practice patterns study. Kidney Int 70(7):1358\u20131366. doi: 10.1038\/sj.ki.5001754","journal-title":"Kidney Int"},{"issue":"1","key":"404_CR10","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/ki.2013.279.High","volume":"85","author":"F Tentori","year":"2014","unstructured":"Tentori F, Mccullough K, Kilpatrick RD et al (2014) High rates of death and hospitalization follow bone fracture among hemodialysis patients. Kidney Int 85(1):166\u2013173. doi: 10.1038\/ki.2013.279.High","journal-title":"Kidney Int"},{"issue":"11","key":"404_CR11","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.1681\/ASN.2005111194","volume":"17","author":"TL Nickolas","year":"2006","unstructured":"Nickolas TL, McMahon DJ, Shane E (2006) Relationship between moderate to severe kidney disease and hip fracture in the United States. J Am Soc Nephrol 17(11):3223\u20133232. doi: 10.1681\/ASN.2005111194","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"404_CR12","doi-asserted-by":"publisher","first-page":"646","DOI":"10.2215\/CJN.06040614","volume":"10","author":"KL Naylor","year":"2015","unstructured":"Naylor KL, Garg AX, Zou G et al (2015) Comparison of fracture risk prediction among individuals with reduced and normal kidney function. Clin J Am Soc Nephrol 10(4):646\u2013653. doi: 10.2215\/CJN.06040614","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"404_CR13","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/kisup.2013.93","volume":"3","author":"JJ Kazama","year":"2013","unstructured":"Kazama JJ, Iwasaki Y, Fukagawa M (2013) Uremic osteoporosis. Kidney Int Suppl 3(5):446\u2013450. doi: 10.1038\/kisup.2013.93","journal-title":"Kidney Int Suppl"},{"issue":"4","key":"404_CR14","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.rdc.2006.08.003","volume":"32","author":"E Dennison","year":"2006","unstructured":"Dennison E, Mohamed MA, Cooper C (2006) Epidemiology of osteoporosis. Rheum Dis Clin North Am 32(4):617\u2013629. doi: 10.1016\/j.rdc.2006.08.003","journal-title":"Rheum Dis Clin North Am"},{"issue":"6","key":"404_CR15","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s00198-004-1780-5","volume":"16","author":"JA Kanis","year":"2005","unstructured":"Kanis JA, Borgstrom F, De Laet C et al (2005) Assessment of fracture risk. Osteoporos Int 16(6):581\u2013589. doi: 10.1007\/s00198-004-1780-5","journal-title":"Osteoporos Int"},{"key":"404_CR16","doi-asserted-by":"crossref","unstructured":"Genant HK, Li J, Wu CY, Shepherd JA (2000) Vertebral fractures in osteoporosis 3(3):281\u2013290","DOI":"10.1385\/JCD:3:3:281"},{"issue":"1","key":"404_CR17","doi-asserted-by":"publisher","first-page":"73","DOI":"10.5301\/jn.5000212","volume":"26","author":"JB Cannata-And\u00eda","year":"2013","unstructured":"Cannata-And\u00eda JB, Rodriguez Garc\u00eda M, G\u00f3mez Alonso C (2013) Osteoporosis and adynamic bone in chronic kidney disease. J Nephrol 26(1):73\u201380. doi: 10.5301\/jn.5000212","journal-title":"J Nephrol"},{"issue":"3","key":"404_CR18","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.rcl.2010.02.018","volume":"48","author":"D Diacinti","year":"2010","unstructured":"Diacinti D, Guglielmi G (2010) Vertebral morphometry. Radiol Clin North Am 48(3):561\u2013575. doi: 10.1016\/j.rcl.2010.02.018","journal-title":"Radiol Clin North Am"},{"issue":"4","key":"404_CR19","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.jocd.2014.01.009","volume":"17","author":"M Antonelli","year":"2014","unstructured":"Antonelli M, Einstadter D, Magrey M (2014) Screening and treatment of osteoporosis after hip fracture: comparison of sex and race. J Clin Densitom 17(4):479\u2013483. doi: 10.1016\/j.jocd.2014.01.009","journal-title":"J Clin Densitom"},{"issue":"10","key":"404_CR20","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1007\/s00198-009-0920-3","volume":"20","author":"B Abrahamsen","year":"2009","unstructured":"Abrahamsen B, van Staa T, Ariely R, Olson M, Cooper C (2009) Excess mortality following hip fracture: a systematic epidemiological review. Osteoporos Int 20(10):1633\u20131650. doi: 10.1007\/s00198-009-0920-3","journal-title":"Osteoporos Int"},{"issue":"2","key":"404_CR21","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s00467-015-3069-7","volume":"31","author":"VM Brandenburg","year":"2016","unstructured":"Brandenburg VM, D\u2019Haese P, Deck A et al (2016) From skeletal to cardiovascular disease in 12 steps\u2014the evolution of sclerostin as a major player in CKD\u2013MBD. Pediatr Nephrol 31(2):195\u2013206. doi: 10.1007\/s00467-015-3069-7","journal-title":"Pediatr Nephrol"},{"key":"404_CR22","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.12842","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Feng B (2016) Systematic review and meta-analysis for the association of bone mineral density and osteoporosis\/osteopenia with vascular calcification in women. Int J Rheum Dis. doi: 10.1111\/1756-185X.12842","journal-title":"Int J Rheum Dis"},{"issue":"Suppl 1","key":"404_CR23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3265\/Nefrologia.pre2011.Jan.10816","volume":"31","author":"J-V Torregrosa","year":"2011","unstructured":"Torregrosa J-V, Bover J, Cannata Andia J et al (2011) Spanish Society of Nephrology recommendations for controlling mineral and bone disorder in chronic kidney disease patients (S.E.N.-M.B.D.). Nefrologia 31(Suppl 1):3\u201332. doi: 10.3265\/Nefrologia.pre2011.Jan.10816","journal-title":"Nefrologia"},{"key":"404_CR24","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) (2009) KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD\u2013MBD). Off J Int Soc Nephrol Kidney Int 76"},{"issue":"4","key":"404_CR25","doi-asserted-by":"publisher","first-page":"654","DOI":"10.2215\/CJN.07450714","volume":"10","author":"JL Gorriz","year":"2015","unstructured":"Gorriz JL, Molina P, Cerveron MJ et al (2015) Vascular calcification in patients with nondialysis CKD over 3 years. Clin J Am Soc Nephrol 10(4):654\u2013666. doi: 10.2215\/CJN.07450714","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"404_CR26","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1093\/ndt\/gfv021a","volume":"30","author":"J Bover","year":"2015","unstructured":"Bover J, Evenepoel P, Ure\u00f1a-Torres P et al (2015) Opponent\u2019s comments. Nephrol Dial Transpl 30(3):357. doi: 10.1093\/ndt\/gfv021a","journal-title":"Nephrol Dial Transpl"},{"issue":"6","key":"404_CR27","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.semnephrol.2014.09.004","volume":"34","author":"PU Torres","year":"2017","unstructured":"Torres PU, Bover J, Mazzaferro S, de Vernejoul MC, Cohen-Solal M (2017) When, how, and why a bone biopsy should be performed in patients with chronic kidney disease. Semin Nephrol 34(6):612\u2013625. doi: 10.1016\/j.semnephrol.2014.09.004","journal-title":"Semin Nephrol"},{"key":"404_CR28","doi-asserted-by":"publisher","unstructured":"KDIGO (2009) KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD\u2013MBD). Kidney Int Suppl. 113:S1\u2013130. doi: 10.1038\/ki.2009.188","DOI":"10.1038\/ki.2009.188"},{"issue":"10","key":"404_CR29","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1093\/ndt\/gft514","volume":"29","author":"M Cozzolino","year":"2014","unstructured":"Cozzolino M, Urena-Torres P, Vervloet MG et al (2014) Is chronic kidney disease-mineral bone disorder (CKD\u2013MBD) really a syndrome? Nephrol Dial Transpl 29(10):1815\u20131820. doi: 10.1093\/ndt\/gft514","journal-title":"Nephrol Dial Transpl"},{"issue":"5","key":"404_CR30","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1002\/jbmr.2406","volume":"30","author":"SL West","year":"2015","unstructured":"West SL, Lok CE, Langsetmo L et al (2015) Bone mineral density predicts fractures in chronic kidney disease. J Bone Miner Res 30(5):913\u2013919. doi: 10.1002\/jbmr.2406","journal-title":"J Bone Miner Res"},{"issue":"7","key":"404_CR31","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.2215\/CJN.12871211","volume":"7","author":"RH Yenchek","year":"2012","unstructured":"Yenchek RH, Ix JH, Shlipak MG et al (2012) Bone mineral density and fracture risk in older individuals with CKD. Clin J Am Soc Nephrol 7(7):1130\u20131136. doi: 10.2215\/CJN.12871211","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"404_CR32","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1093\/ndt\/gfr317","volume":"27","author":"S Iimori","year":"2012","unstructured":"Iimori S, Mori Y, Akita W et al (2012) Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5D patients-a single-center cohort study. Nephrol Dial Transpl 27(1):345\u2013351. doi: 10.1093\/ndt\/gfr317","journal-title":"Nephrol Dial Transpl"},{"issue":"3","key":"404_CR33","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s40620-015-0232-y","volume":"29","author":"F Aucella","year":"2016","unstructured":"Aucella F, Brunori G, Dalmartello M et al (2016) Assessment of the geriatric competence and perceived needs of Italian nephrologists: an internet survey. J Nephrol 29(3):385\u2013390. doi: 10.1007\/s40620-015-0232-y","journal-title":"J Nephrol"},{"issue":"10","key":"404_CR34","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","volume":"25","author":"F Cosman","year":"2014","unstructured":"Cosman F, de Beur SJ, LeBoff MS et al (2014) Clinician\u2019s guide to prevention and treatment of osteoporosis. Osteoporos Int 25(10):2359\u20132381. doi: 10.1007\/s00198-014-2794-2","journal-title":"Osteoporos Int"},{"key":"404_CR35","doi-asserted-by":"publisher","first-page":"c3691","DOI":"10.1136\/bmj.c3691","volume":"341","author":"MJ Bolland","year":"2010","unstructured":"Bolland MJ, Avenell A, Baron JA et al (2010) Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ 341:c3691. doi: 10.1136\/bmj.c3691","journal-title":"BMJ"},{"issue":"16","key":"404_CR36","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1056\/NEJMcp1210380","volume":"369","author":"DC Bauer","year":"2013","unstructured":"Bauer DC (2013) calcium supplements and fracture prevention. N Engl J Med 369(16):1537\u20131543. doi: 10.1056\/NEJMcp1210380","journal-title":"N Engl J Med"},{"issue":"9811","key":"404_CR37","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0140-6736(11)60178-5","volume":"379","author":"AS Levey","year":"2012","unstructured":"Levey AS, Coresh J (2012) Chronic kidney disease. Lancet 379(9811):165\u2013180. doi: 10.1016\/S0140-6736(11)60178-5","journal-title":"Lancet"},{"issue":"9887","key":"404_CR38","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/S0140-6736(13)60439-0","volume":"382","author":"K-U Eckardt","year":"2013","unstructured":"Eckardt K-U, Coresh J, Devuyst O et al (2013) Evolving importance of kidney disease: from subspecialty to global health burden. Lancet 382(9887):158\u2013169. doi: 10.1016\/S0140-6736(13)60439-0","journal-title":"Lancet"},{"issue":"9941","key":"404_CR39","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/S0140-6736(14)61267-8","volume":"384","author":"Chronic kidney disease","year":"2014","unstructured":"Chronic kidney disease (2014) Refi ning diagnosis and management Polio eradication: placing health before conflict. Lancet 384(9941):378. doi: 10.1016\/S0140-6736(14)61267-8","journal-title":"Lancet"},{"issue":"5","key":"404_CR40","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1038\/ki.2012.403","volume":"83","author":"KM Hill","year":"2013","unstructured":"Hill KM, Martin BR, Wastney ME et al (2013) Oral calcium carbonate affects calcium but not phosphorus balance in stage 3\u20134 chronic kidney disease. Kidney Int 83(5):959\u2013966. doi: 10.1038\/ki.2012.403","journal-title":"Kidney Int"},{"issue":"11","key":"404_CR41","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1038\/ki.2011.490","volume":"81","author":"DM Spiegel","year":"2012","unstructured":"Spiegel DM, Brady K (2012) Calcium balance in normal individuals and in patients with chronic kidney disease on low- and high-calcium diets. Kidney Int 81(11):1116\u20131122. doi: 10.1038\/ki.2011.490","journal-title":"Kidney Int"},{"issue":"7","key":"404_CR42","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1056\/NEJMoa055218","volume":"354","author":"D Jr","year":"2006","unstructured":"Jr D, La Z, Margery G et al (2006) Calcium plus Vitamin D supplementation and the risk of fractures. N Engl J Med 354(7):669\u2013683. doi: 10.1056\/NEJMoa055218","journal-title":"N Engl J Med"},{"key":"404_CR43","doi-asserted-by":"publisher","unstructured":"Agarwal R, Georgianos PI (2016) Con: nutritional vitamin D replacement in chronic kidney disease and end-stage renal disease. Polar views in nephrology. JAMA 706\u2013713. doi: 10.1093\/ndt\/gfw080","DOI":"10.1093\/ndt\/gfw080"},{"issue":"7","key":"404_CR44","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1001\/jama.2012.159","volume":"307","author":"SD Anker","year":"2012","unstructured":"Anker SD, von Haehling S (2012) Vitamin D in chronic kidney disease. JAMA 307(7):722. doi: 10.1001\/jama.2012.159","journal-title":"JAMA"},{"issue":"5","key":"404_CR45","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1093\/ndt\/gfw082","volume":"31","author":"DJA Goldsmith","year":"2016","unstructured":"Goldsmith DJA (2016) Pro: should we correct vitamin D deficiency\/insufficiency in chronic kidney disease patients with inactive forms of vitamin D or just treat them with active vitamin D forms?: Table 1. Nephrol Dial Transpl 31(5):698\u2013705. doi: 10.1093\/ndt\/gfw082","journal-title":"Nephrol Dial Transpl"},{"issue":"2","key":"404_CR46","doi-asserted-by":"publisher","first-page":"109","DOI":"10.7326\/M14-1659","volume":"162","author":"ES LeBlanc","year":"2015","unstructured":"LeBlanc ES, Zakher B, Daeges M, Pappas M, Chou R (2015) Screening for vitamin D deficiency: a systematic review for the U.S. preventive services task force. Ann Intern Med 162(2):109. doi: 10.7326\/M14-1659","journal-title":"Ann Intern Med"},{"issue":"2","key":"404_CR47","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1001\/jamainternmed.2015.7148","volume":"176","author":"HA Bischoff-Ferrari","year":"2016","unstructured":"Bischoff-Ferrari HA, Dawson-Hughes B, Orav EJ et al (2016) Monthly high-dose vitamin D treatment for the prevention of functional decline. JAMA Intern Med 176(2):175. doi: 10.1001\/jamainternmed.2015.7148","journal-title":"JAMA Intern Med"},{"issue":"1","key":"404_CR48","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1056\/NEJMoa1109617","volume":"367","author":"HA Bischoff-Ferrari","year":"2012","unstructured":"Bischoff-Ferrari HA, Willett WC, Orav EJ et al (2012) A pooled analysis of vitamin D Dose requirements for fracture prevention. N Engl J Med 367(1):40\u201349. doi: 10.1056\/NEJMoa1109617","journal-title":"N Engl J Med"},{"issue":"2","key":"404_CR49","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s00774-013-0480-7","volume":"32","author":"F Mac-Way","year":"2014","unstructured":"Mac-Way F, Azzouz L, Noel C, Lafage-Proust M-H (2014) Osteomalacia induced by vitamin D deficiency in hemodialysis patients: the crucial role of vitamin D correction. J Bone Miner Metab 32(2):215\u2013219. doi: 10.1007\/s00774-013-0480-7","journal-title":"J Bone Miner Metab"},{"issue":"4","key":"404_CR50","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/ncpneph0443","volume":"3","author":"JD Hernandez","year":"2007","unstructured":"Hernandez JD, Wesseling K, Boechat MI, Gales B, Salusky IB (2007) Osteomalacia in a hemodialysis patient receiving an active vitamin D sterol. Nat Clin Pract Nephrol 3(4):227\u2013232. doi: 10.1038\/ncpneph0443","journal-title":"Nat Clin Pract Nephrol"},{"key":"404_CR51","doi-asserted-by":"crossref","unstructured":"Drake MT, Clarke BL, Khosla S (2008) Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 83(9):1032\u20131045. http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC2667901\/","DOI":"10.4065\/83.9.1032"},{"issue":"2","key":"404_CR52","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00198-007-0540-8","volume":"30","author":"F Festuccia","year":"2017","unstructured":"Festuccia F, Jafari MT, Fofi C et al (2017) Safety and efficacy of denosumab in osteoporotic hemodialysed patients. J Nephrol 30(2):271\u2013279. doi: 10.1007\/s00198-007-0540-8","journal-title":"J Nephrol"},{"issue":"1","key":"404_CR53","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2215\/CJN.02550508","volume":"4","author":"ND Toussaint","year":"2009","unstructured":"Toussaint ND, Elder GJ, Kerr PG (2009) Bisphosphonates in chronic kidney disease; balancing potential benefits and adverse effects on bone and soft tissue. Clin J Am Soc Nephrol 4(1):221\u2013233. doi: 10.2215\/CJN.02550508","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"404_CR54","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.bone.2010.08.008","volume":"49","author":"T Bellido","year":"2011","unstructured":"Bellido T, Plotkin LI (2011) Novel actions of bisphosphonates in bone: preservation of osteoblast and osteocyte viability. Bone 49(1):50\u201355. doi: 10.1016\/j.bone.2010.08.008","journal-title":"Bone"},{"issue":"1","key":"404_CR55","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s00198-012-2074-y","volume":"24","author":"JA Kanis","year":"2013","unstructured":"Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster JY (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 24(1):23\u201357. doi: 10.1007\/s00198-012-2074-y","journal-title":"Osteoporos Int"},{"issue":"4","key":"404_CR56","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.maturitas.2013.05.013","volume":"75","author":"J Compston","year":"2013","unstructured":"Compston J, Bowring C, Cooper A et al (2013) Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013. Maturitas 75(4):392\u2013396. doi: 10.1016\/j.maturitas.2013.05.013","journal-title":"Maturitas"},{"issue":"3","key":"404_CR57","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1177\/1759720X13477714","volume":"5","author":"DL Diab","year":"2013","unstructured":"Diab DL, Watts NB (2013) Bisphosphonate drug holiday: who, when and how long. Ther Adv Musculoskelet Dis 5(3):107\u2013111. doi: 10.1177\/1759720X13477714","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"404_CR58","doi-asserted-by":"publisher","first-page":"192320","DOI":"10.1155\/2014\/192320","volume":"2014","author":"EA Sigua-Rodriguez","year":"2014","unstructured":"Sigua-Rodriguez EA, da Costa Ribeiro R, de Brito ACR, Alvarez-Pinzon N, de Albergaria-Barbosa JR (2014) Bisphosphonate-related osteonecrosis of the jaw: a review of the literature. Int J Dent 2014:192320. doi: 10.1155\/2014\/192320","journal-title":"Int J Dent"},{"issue":"11","key":"404_CR59","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.14219\/jada.archive.2011.0108","volume":"142","author":"JW Hellstein","year":"2011","unstructured":"Hellstein JW, Adler RA, Edwards B et al (2011) Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis. J Am Dent Assoc 142(11):1243\u20131251. doi: 10.14219\/jada.archive.2011.0108","journal-title":"J Am Dent Assoc"},{"issue":"1","key":"404_CR60","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/jbmr.2405","volume":"30","author":"AA Khan","year":"2015","unstructured":"Khan AA, Morrison A, Hanley DA et al (2015) Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res 30(1):3\u201323. doi: 10.1002\/jbmr.2405","journal-title":"J Bone Miner Res"},{"issue":"6","key":"404_CR61","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.bone.2003.08.004","volume":"33","author":"DB Burr","year":"2003","unstructured":"Burr DB, Miller L, Grynpas M et al (2003) Tissue mineralization is increased following 1-year treatment with high doses of bisphosphonates in dogs. Bone 33(6):960\u2013969","journal-title":"Bone"},{"issue":"10","key":"404_CR62","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1359\/jbmr.070609","volume":"22","author":"RD Chapurlat","year":"2007","unstructured":"Chapurlat RD, Arlot M, Burt-Pichat B et al (2007) Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study. J Bone Miner Res 22(10):1502\u20131509","journal-title":"J Bone Miner Res"},{"issue":"5","key":"404_CR63","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S8756-3282(00)00376-8","volume":"27","author":"GY Boivin","year":"2000","unstructured":"Boivin GY, Chavassieux PM, Santora AC, Yates J, Meunier PJ (2000) Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 27(5):687\u2013694","journal-title":"Bone"},{"issue":"3","key":"404_CR64","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1210\/jc.2004-0952","volume":"90","author":"CV Odvina","year":"2005","unstructured":"Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CYC (2005) Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 90(3):1294\u20131301","journal-title":"J Clin Endocrinol Metab"},{"issue":"19","key":"404_CR65","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1056\/NEJMc062268","volume":"355","author":"R Armamento-Villareal","year":"2006","unstructured":"Armamento-Villareal R, Napoli N, Panwar V, Novack D (2006) Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis. N Engl J Med 355(19):2048\u20132050","journal-title":"N Engl J Med"},{"key":"404_CR66","doi-asserted-by":"publisher","unstructured":"Ma S, Goh EL, Jin A et al (2017) Long-term effects of bisphosphonate therapy: perforations, microcracks and mechanical properties. Nat Publ Gr (November 2016) 1\u201310. doi: 10.1038\/srep43399","DOI":"10.1038\/srep43399"},{"issue":"4","key":"404_CR67","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1177\/2040622315584114","volume":"6","author":"Y Saita","year":"2015","unstructured":"Saita Y, Ishijima M, Kaneko K (2015) Atypical femoral fractures and bisphosphonate use: current evidence and clinical implications. Ther Adv Chronic Dis 6(4):185\u2013193. doi: 10.1177\/2040622315584114","journal-title":"Ther Adv Chronic Dis"},{"key":"404_CR68","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1056\/NEJMoa0904327","volume":"309","author":"DM Black","year":"2010","unstructured":"Black DM, Kelly MP, Genant HK, Palermo L, Eastell R, Bucci-Rechtweg C, Cauley J, Leung PC, Boonen S, Santora A, de Papp A, Bauer DC, For the FIT, Committees and HPFTS (2010) Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 309:1761\u20131771. doi: 10.1056\/NEJMoa0904327","journal-title":"N Engl J Med"},{"issue":"24","key":"404_CR69","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","volume":"296","author":"DM Black","year":"2006","unstructured":"Black DM, Schwartz AV, Ensrud KE et al (2006) Effects of continuing or stopping alendronate after 5 years of treatment: The fracture intervention trial long-term extension (flex): a randomized trial. JAMA 296(24):2927\u20132938. doi: 10.1001\/jama.296.24.2927","journal-title":"JAMA"},{"key":"404_CR70","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa030897","volume":"350","author":"HG Bone","year":"2004","unstructured":"Bone HG (2004) Ten years\u2019 experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350:1189\u20131199. 10.1056\/NEJMoa030897","journal-title":"N Engl J Med"},{"key":"404_CR71","doi-asserted-by":"crossref","unstructured":"Whitaker M, Guo J, Ph D, Kehoe T, Benson G (2012) Bisphosphonates for osteoporosis\u2014where do we go. N Engl J Med","DOI":"10.1056\/NEJMp1202619"},{"issue":"3","key":"404_CR72","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1159\/000276666","volume":"29","author":"R Amerling","year":"2010","unstructured":"Amerling R, Harbord NB, Pullman J, Feinfeld DA (2010) Bisphosphonate use in chronic kidney disease: association with adynamic bone disease in a bone histology series. Blood Purif 29(3):293\u2013299. doi: 10.1159\/000276666","journal-title":"Blood Purif"},{"issue":"6","key":"404_CR73","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.semnephrol.2014.09.008","volume":"34","author":"J Bover","year":"2014","unstructured":"Bover J, Urena P, Brandenburg V et al (2014) Adynamic bone disease: from bone to vessels in chronic kidney disease. Semin Nephrol 34(6):626\u2013640. doi: 10.1016\/j.semnephrol.2014.09.008","journal-title":"Semin Nephrol"},{"issue":"3","key":"404_CR74","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1093\/ndtplus\/sfn040","volume":"1","author":"VM Brandenburg","year":"2008","unstructured":"Brandenburg VM, Floege J (2008) Adynamic bone disease\u2014bone and beyond. NDT Plus 1(3):135\u2013147. doi: 10.1093\/ndtplus\/sfn040","journal-title":"NDT Plus"},{"issue":"6","key":"404_CR75","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1016\/j.kint.2016.06.041","volume":"90","author":"P Evenepoel","year":"2016","unstructured":"Evenepoel P, Bover J, Ure\u00f1a Torres P (2016) Parathyroid hormone metabolism and signaling in health and chronic kidney disease. Kidney Int 90(6):1184\u20131190. doi: 10.1016\/j.kint.2016.06.041","journal-title":"Kidney Int"},{"issue":"3","key":"404_CR76","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/ki.2014.425","volume":"87","author":"M Ketteler","year":"2015","unstructured":"Ketteler M, Elder GJ, Evenepoel P et al (2015) Revisiting KDIGO clinical practice guideline on chronic kidney disease-mineral and bone disorder: a commentary from a Kidney Disease: improving global outcomes controversies conference. Kidney Int 87(3):502\u2013528. doi: 10.1038\/ki.2014.425","journal-title":"Kidney Int"},{"issue":"4","key":"404_CR77","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1359\/jbmr.070112","volume":"22","author":"SA Jamal","year":"2007","unstructured":"Jamal SA, Bauer DC, Ensrud KE et al (2007) Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. J Bone Miner Res 22(4):503\u2013508. doi: 10.1359\/jbmr.070112","journal-title":"J Bone Miner Res"},{"key":"404_CR78","doi-asserted-by":"publisher","unstructured":"Miller PD, Roux C, Boonen S et al (2005) Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the cockcroft and gault method: a pooled analysis of nine. Clin Trials 20(12). doi: 10.1359\/JBMR.050817","DOI":"10.1359\/JBMR.050817"},{"issue":"1","key":"404_CR79","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1053\/j.ajkd.2009.12.039","volume":"56","author":"ND Toussaint","year":"2010","unstructured":"Toussaint ND, Lau KK, Strauss BJ, Polkinghorne KR, Kerr PG (2010) Effect of alendronate on vascular calcification in CKD stages 3 and 4: a pilot randomized controlled trial. Am J Kidney Dis 56(1):57\u201368. doi: 10.1053\/j.ajkd.2009.12.039","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"404_CR80","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/ki.2008.646","volume":"75","author":"KA Lomashvili","year":"2009","unstructured":"Lomashvili KA, Monier-Faugere MC, Wang X, Malluche HH, O\u2019Neill WC (2009) Effect of bisphosphonates on vascular calcification and bone metabolism in experimental renal failure. Kidney Int 75(6):617\u2013625. doi: 10.1038\/ki.2008.646","journal-title":"Kidney Int"},{"issue":"9","key":"404_CR81","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1007\/s00198-016-3607-6","volume":"27","author":"C Beaudoin","year":"2016","unstructured":"Beaudoin C, Jean S, Bessette L, Ste-Marie L-G, Moore L, Brown JP (2016) Denosumab compared to other treatments to prevent or treat osteoporosis in individuals at risk of fracture: a systematic review and meta-analysis. Osteoporos Int 27(9):2835\u20132844. doi: 10.1007\/s00198-016-3607-6","journal-title":"Osteoporos Int"},{"issue":"2","key":"404_CR82","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1002\/jbmr.2043","volume":"29","author":"EJ Samelson","year":"2014","unstructured":"Samelson EJ, Miller PD, Christiansen C et al (2014) RANKL inhibition with denosumab does not influence 3-year progression of aortic calcification or incidence of adverse cardiovascular events in postmenopausal women with osteoporosis and high cardiovascular risk. J Bone Miner Res 29(2):450\u2013457. doi: 10.1002\/jbmr.2043","journal-title":"J Bone Miner Res"},{"issue":"8","key":"404_CR83","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1002\/jbmr.403","volume":"26","author":"SA Jamal","year":"2011","unstructured":"Jamal SA, Ljunggren \u00d6, Stehman-Breen C et al (2011) Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res 26(8):1829\u20131835. doi: 10.1002\/jbmr.403","journal-title":"J Bone Miner Res"},{"key":"404_CR84","doi-asserted-by":"publisher","unstructured":"Aapro M, De Castro G, Cohen E, Deray G, Dooley M (2015) Renal effects of molecular targeted therapies in oncology: a review by the cancer and the kidney. 252\u2013255. doi: 10.1093\/annonc\/mdv136","DOI":"10.1093\/annonc\/mdv136"},{"key":"404_CR85","doi-asserted-by":"publisher","unstructured":"Block GA, Bone HG, Fang L, Lee E, Padhi D (2012) A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res 27(7):1471\u20131479. doi: 10.1002\/jbmr.1613","DOI":"10.1002\/jbmr.1613"},{"issue":"11","key":"404_CR86","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1111\/imj.12283","volume":"43","author":"N Farinola","year":"2013","unstructured":"Farinola N, Kanjanapan Y (2013) Denosumab-induced hypocalcaemia in high bone turnover states of malignancy and secondary hyperparathyroidism from renal failure. Intern Med J 43(11):1243\u20131246. doi: 10.1111\/imj.12283","journal-title":"Intern Med J"},{"key":"404_CR87","doi-asserted-by":"crossref","unstructured":"Dave V, Chiang CY, Booth J, Mount PF (2015) Hypocalcemia post denosumab in patients with chronic kidney disease stage 4\u20135. Am J Nephrol 41(2):129\u2013137. http:\/\/www.karger.com\/DOI\/10.1159\/000380960","DOI":"10.1159\/000380960"},{"issue":"8","key":"404_CR88","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1111\/nep.12432","volume":"20","author":"G Lambe","year":"2015","unstructured":"Lambe G, Malvathu R, Thomas HM, Graves A (2015) Hypocalcaemic tetany occurring post a single denosumab dose in a patient with stage 4 chronic kidney disease, followed by calcium- and calcitriol-induced hypercalcaemia. Nephrology 20(8):583\u2013584. doi: 10.1111\/nep.12432","journal-title":"Nephrology"},{"issue":"9","key":"404_CR89","first-page":"1309","volume":"26","author":"T Hamano","year":"2016","unstructured":"Hamano T, Nakano C (2016) Is denosmab really effective and safe in the care of CKD\u2013MBD? Clin Calcium 26(9):1309","journal-title":"Clin Calcium"},{"issue":"1","key":"404_CR90","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s00198-006-0189-8","volume":"18","author":"PD Miller","year":"2007","unstructured":"Miller PD, Schwartz EN, Chen P, Misurski DA, Krege JH (2007) Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporos Int 18(1):59\u201368. doi: 10.1007\/s00198-006-0189-8","journal-title":"Osteoporos Int"},{"issue":"1","key":"404_CR91","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1093\/ckj\/sfs148","volume":"6","author":"FP Schena","year":"2013","unstructured":"Schena FP, Ayasreh N, Fernandez-Llama P et al (2013) Recombinant PTH associated with hypercalcaemia and renal failure. Clin Kidney J 6(1):93\u201395. doi: 10.1093\/ckj\/sfs148","journal-title":"Clin Kidney J"},{"key":"404_CR92","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.bone.2017.03.006","volume":"98","author":"BZ Leder","year":"2017","unstructured":"Leder BZ, Tsai JN, Jiang LA, Lee H (2017) Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: the Denosumab and teriparatide follow-up study (DATA-follow-up). Bone 98:54\u201358. doi: 10.1016\/j.bone.2017.03.006","journal-title":"Bone"},{"key":"404_CR93","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3081","author":"NB Watts","year":"2017","unstructured":"Watts NB, Aggers D, McCarthy EF et al (2017) Responses to treatment with teriparatide in patients with atypical femur fractures previously treated with bisphosphonates. J Bone Miner Res. doi: 10.1002\/jbmr.3081","journal-title":"J Bone Miner Res"},{"key":"404_CR94","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.2147\/CIA.S120175","volume":"11","author":"A Nishikawa","year":"2016","unstructured":"Nishikawa A, Yoshiki F, Taketsuna M, Kajimoto K, Enomoto H (2016) Safety and effectiveness of daily teriparatide for osteoporosis in patients with severe stages of chronic kidney disease: post hoc analysis of a postmarketing observational study. Clin Interv Aging 11:1653\u20131659. doi: 10.2147\/CIA.S120175","journal-title":"Clin Interv Aging"},{"issue":"2","key":"404_CR95","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1093\/ckj\/sfv005","volume":"8","author":"P Giamalis","year":"2015","unstructured":"Giamalis P, Economidou D, Dimitriadis C, Memmos D, Papagianni A, Efstratiadis G (2015) Treatment of adynamic bone disease in a haemodialysis patient with teriparatide. Clin Kidney J 8(2):188\u2013190. doi: 10.1093\/ckj\/sfv005","journal-title":"Clin Kidney J"},{"issue":"3","key":"404_CR96","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1159\/000316708","volume":"33","author":"D Cejka","year":"2010","unstructured":"Cejka D, Kodras K, Bader T, Haas M (2010) Treatment of hemodialysis-associated adynamic bone disease with teriparatide (PTH1-34): a pilot study. Kidney Blood Press Res 33(3):221\u2013226. doi: 10.1159\/000316708","journal-title":"Kidney Blood Press Res"},{"issue":"7","key":"404_CR97","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1001\/jama.2016.11136","volume":"316","author":"PD Miller","year":"2016","unstructured":"Miller PD, Hattersley G, Riis BJ et al (2016) Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA 316(7):722\u2013733. doi: 10.1001\/jama.2016.11136","journal-title":"JAMA"},{"issue":"5","key":"404_CR98","doi-asserted-by":"publisher","first-page":"140101140147009","DOI":"10.1056\/NEJMoa1305224","volume":"370","author":"MR McClung","year":"2014","unstructured":"McClung MR, Grauer A, Boonen S et al (2014) Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 370(5):140101140147009. doi: 10.1056\/NEJMoa1305224","journal-title":"N Engl J Med"},{"issue":"16","key":"404_CR99","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman F, Crittenden DB, Adachi JD et al (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375(16):1532\u20131543. doi: 10.1056\/NEJMoa1607948","journal-title":"N Engl J Med"},{"issue":"2","key":"404_CR100","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1080\/14712598.2017.1280455","volume":"17","author":"L Bandeira","year":"2017","unstructured":"Bandeira L, Lewiecki EM, Bilezikian JP (2017) Romosozumab for the treatment of osteoporosis. Expert Opin Biol Ther 17(2):255\u2013263. doi: 10.1080\/14712598.2017.1280455","journal-title":"Expert Opin Biol Ther"},{"key":"404_CR101","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2016.12.012","author":"MR McClung","year":"2017","unstructured":"McClung MR (2017) Clinical utility of anti-sclerostin antibodies. Bone. doi: 10.1016\/j.bone.2016.12.012","journal-title":"Bone"},{"key":"404_CR102","doi-asserted-by":"publisher","unstructured":"Moe SM, Chen NX, Newman CL et al (2015) Anti\u2014sclerostin antibody treatment in a rat model of progressive renal osteodystrophy. J Bone Miner Res 30(3):499\u2013509. doi: 10.1002\/jbmr.2372","DOI":"10.1002\/jbmr.2372"},{"issue":"2","key":"404_CR103","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1677\/joe.1.06059","volume":"185","author":"R Eastell","year":"2005","unstructured":"Eastell R (2005) Role of oestrogen in the regulation of bone turnover at the menarche. J Endocrinol 185(2):223\u2013234. doi: 10.1677\/joe.1.06059","journal-title":"J Endocrinol"},{"issue":"2","key":"404_CR104","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1053\/j.ackd.2007.01.002","volume":"14","author":"P Anantharaman","year":"2007","unstructured":"Anantharaman P, Schmidt RJ (2007) Sexual function in chronic kidney disease. Adv Chronic Kidney Dis 14(2):119\u2013125. doi: 10.1053\/j.ackd.2007.01.002","journal-title":"Adv Chronic Kidney Dis"},{"issue":"6","key":"404_CR105","first-page":"461","volume":"8","author":"F Haghverdi","year":"2014","unstructured":"Haghverdi F, Farbodara T, Mortaji S, Soltani P, Saidi N (2014) Effect of raloxifene on parathyroid hormone in osteopenic and osteoporotic postmenopausal women with chronic kidney disease stage 5. Iran J Kidney Dis 8(6):461\u2013466","journal-title":"Iran J Kidney Dis"},{"issue":"6","key":"404_CR106","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1046\/j.1523-1755.2003.00005.x","volume":"63","author":"E Hern\u00e1ndez","year":"2003","unstructured":"Hern\u00e1ndez E, Valera R, Alonzo E et al (2003) Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis. Kidney Int 63(6):2269\u20132274. doi: 10.1046\/j.1523-1755.2003.00005.x","journal-title":"Kidney Int"},{"issue":"7","key":"404_CR107","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1681\/ASN.2007050555","volume":"19","author":"A Ishani","year":"2008","unstructured":"Ishani A, Blackwell T, Jamal SA, Cummings SR, Ensrud KE, Investigators for the M (2008) The effect of raloxifene treatment in postmenopausal women with CKD. J Am Soc Nephrol 19(7):1430\u20131438. doi: 10.1681\/ASN.2007050555","journal-title":"J Am Soc Nephrol"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40620-017-0404-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-017-0404-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-017-0404-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:56:52Z","timestamp":1777564612000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/30\/5\/677\/8371231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,21]]},"references-count":107,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["404"],"URL":"https:\/\/doi.org\/10.1007\/s40620-017-0404-z","relation":{},"ISSN":["1121-8428","1724-6059"],"issn-type":[{"value":"1121-8428","type":"print"},{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,21]]}}}